go to contents

Hookipa Biotech AG

Back to list

Facts

Founded
2011
Staff
112
Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health

Profile

HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

R&D:HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial. Our non-replicating prophylactic Cytomegalovirus candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation.

Similar companies in RDM biotech/pharma

ChironWells GmbH

Organization type
RDM biotech/pharma
Region
Tyrol
Focus
human health
Details

Attoquant Diagnostics GmbH

Organization type
RDM biotech/pharma
Region
Vienna
Cluster
LISAvienna
Focus
human health
Details

Oxford Antibiotic Group GmbH

Organization type
RDM biotech/pharma
Region
Lower Austria
Cluster
ecoplus
Focus
human health
Details

NP Life Science Technologies KG

Organization type
RDM biotech/pharma
Region
Upper Austria
Focus
non-specific applications
Details

Contact

Helmut-Qualtinger-Gasse 2
1030 Wien
Vienna

Contact: Jörn Aldag (CEO)
Email: office@hookipapharma.com
Website